tiprankstipranks
Q32 Bio Announces Mixed Results in Clinical Trials
PremiumCompany AnnouncementsQ32 Bio Announces Mixed Results in Clinical Trials
2M ago
Q32 Bio price target lowered to $20 from $85 at Piper Sandler
Premium
The Fly
Q32 Bio price target lowered to $20 from $85 at Piper Sandler
2M ago
Q32 Bio downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Q32 Bio downgraded to Market Perform from Outperform at Leerink
2M ago
Q32 Bio Advances Clinical Trials Amidst Financial Challenges
PremiumCompany AnnouncementsQ32 Bio Advances Clinical Trials Amidst Financial Challenges
3M ago
Q32 Bio Inc Grapples with Internal Control Challenges Amid Compliance Costs
Premium
Company Announcements
Q32 Bio Inc Grapples with Internal Control Challenges Amid Compliance Costs
3M ago
Q32 Bio reports Q3 EPS ($1.46), consensus ($1.40)
Premium
The Fly
Q32 Bio reports Q3 EPS ($1.46), consensus ($1.40)
3M ago
Q32 Bio Advances in Atopic Dermatitis Treatment Trial
PremiumCompany AnnouncementsQ32 Bio Advances in Atopic Dermatitis Treatment Trial
7M ago
Q32 Bio completes enrollment in SIGNAL-AD clinical trial
Premium
The Fly
Q32 Bio completes enrollment in SIGNAL-AD clinical trial
7M ago
Q32 Bio to join Russell 3000 Index
Premium
The Fly
Q32 Bio to join Russell 3000 Index
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100